Trial reportBMC psychiatry2026
Efficacy of micro-video psychological training camp for reducing depression and anxiety and enhancing resilience: a randomized controlled trial.
Trial report in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundDepression and anxiety disorders are highly prevalent and frequently co-occur, a comorbidity associated with greater chronicity and symptom severity. Access to evidence-based psychological interventions remains limited, particularly in resource-constrained settings. Digital interventions offer a scalable solution. This study evaluated the feasibility, acceptability, and preliminary efficacy of the Micro-Video Psychological Training Camp (MVPTC), a fully automated digital intervention based on integrative psychotherapy principles and targeting mild-to-moderate depression/anxiety and multidimensional mental health.
methodsIn this randomized controlled trial, 204 adults (aged 18–70) with mild-to-moderate symptoms were allocated to either the MVPTC intervention (8 self-guided sessions, n = 97) or waitlist control group (n = 107). The severity of depressive and anxiety symptoms served as primary outcomes, and psychological resilience as a secondary outcome. Exploratory outcomes included sleep quality, coping strategies, and perceived social support. All were measured at baseline, post-intervention, and at 1-month and 3-month follow-ups. Feasibility (dropout and adherence rates) and acceptability (satisfaction ratings) were also assessed.
resultsParticipants (mean age 30.68 years, SD 7.6; 66.2% female, 33.8% male) exhibited a 36.08% dropout rate in the MVPTC group versus 8.41% in control group. The intervention led to significant, sustained reductions in depressive symptoms (Cohen’s d = 0.87 at T2, 0.99 at T3, 0.80 at T4; all P < 0.01) and anxiety symptoms (Cohen’s d = 0.71 at T2, 0.75 at T3, 0.63 at T4; P ≤ 0.01). Significant improvements were also observed in psychological resilience (Cohen’s d =-0.97 at T3, -0.84 at T4; P < 0.01) and sleep quality (ISI: Cohen’s d = 0.97–1.08; P ≤ 0.01). Coping strategies improved transiently (Cohen’s d =-0.58 at T2, -0.53 at T3; P < 0.05), while perceived social support showed no sustained group differences despite temporary family/friend support increases at T3 (Cohen’s d =-0.55 to -0.68; P < 0.05). Participants rated the intervention as acceptable, with an average satisfaction score of 3.06 out of 4 (SD = 0.41; n = 44).
conclusionsThe MVPTC is a promising, fully automated digital intervention that significantly and sustainably reduced core symptoms of depression and anxiety while enhancing psychological resilience and sleep quality over a 3-month period in adults with mild-to-moderate symptoms. Its effects on coping strategies and social support were less enduring. The program demonstrates potential for scalable implementation. Future research should focus on strategies to improve adherence and evaluate its effectiveness in broader, real-world settings.
trial registrationRegistered on Chinese Clinical Trial Registry (ChiCTR2100043725). Registered: February 27, 2021, http://www.chictr.org.cn/ .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.